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Background: Saliva is increasingly promoted as an alternative diagnostic bio-sample to blood; however its role in
respiratory disease requires elucidation. Our aim was to investigate whether C-reactive protein (CRP), procalcitonin (PCT)
and neutrophil elastase (NE) could be measured in unstimulated whole saliva, and to explore differences between
COPD patients and controls with normal lung function. We also determined the relationship between these salivary
biomarkers and self-reported COPD-relevant metrics.
Methods: Salivary CRP, PCT and NE levels were measured at each of 3 visits over a 14-day period alongside spirometry
and a daily self-assessment dairy in 143 subjects: 20 never-smokers and 25 smokers with normal spirometry; 98 COPD
patients [GOLD Stage I, 16; Stage II, 32; Stage III, 39; Stage IV, 11]. Twenty-two randomly selected subjects provided
simultaneous blood samples.
Results: Levels of each salivary biomarker could distinguish between the above cohorts. Significant differences
remained for salivary CRP and NE (p < 0.05) following adjustment for age, gender, sampling time, gum disease
and total co-morbidities; but not for BMI except for salivary NE, which remained higher in smokers compared to
non-smokers and stable COPD subjects (p < 0.001). Patients with acute COPD exacerbations had a median increase in
all 3 salivary biomarkers (p < 0.001); CRP: median 5.74 ng/ml, [interquartile range (IQR) 2.86–12.25], PCT 0.38 ng/ml,
[IQR 0.22–0.94], and NE 539 ng/ml, [IQR 112.25–1264]. In COPD patients, only salivary CRP and PCT levels correlated with
breathing scores (r = 0.14, p < 0.02; r = 0.13, p < 0.03 respectively) and sputum features but not with activities of daily
living. Salivary CRP and PCT concentrations strongly correlated with serum counterparts [r = 0.82, (95 % CI: 0.72–0.87),
p < 0.001 by Spearman’s; and r = 0.53, (95 % CI: 0.33–0.69), p < 0.006 respectively]; salivary NE did not.
Conclusions: CRP, PCT and NE were reliably and reproducibly measured in saliva, providing clinically-relevant
information on health status in COPD; additionally NE distinguished smoking status. All 3 salivary biomarkers increased
during COPD exacerbations, with CRP and PCT correlating well with patient-derived clinical metrics. These results
provide the conceptual basis for further development of saliva as a viable bio-sample in COPD monitoring and
exacerbation management.
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Saliva is increasingly used as a non-invasive easily ac-
cessible bio-sample for point-of-care diagnostics instead
of blood [1, 2] to inform on infection [3–7], drugs [8]
and disease states [9–18], including airways inflamma-
tion. Salivary eosinophil cationic protein can differentiate
between asthmatic and healthy subjects [19]. Increased
salivary CRP and haptoglobin levels are demonstrated in
childhood allergic asthma [20]; raised salivary leukotriene
levels differentiate aspirin-intolerant asthmatics from
tolerant counterparts [21].
Biomarkers in various body fluids have been associated
with Chronic Obstructive Pulmonary Disease (COPD)
pathogenesis and clinical outcome [22, 23]. Serum and
sputum CRP are elevated in COPD patients and healthy
smokers [24, 25], with moderate inverse correlation of
serum CRP to Forced Expiratory Volume in 1 s (FEV1)
[26]. Serum CRP increases during exacerbations [27–32];
with high levels at 14 days post-exacerbation predicting
re-exacerbation within 50 days and poor outcome [33].
Serum Procalcitonin (PCT) shows strong correlation to
bacterial exacerbations [34], guiding antibiotic prescrip-
tions [29, 35]. Neutrophil elastase (NE), mediator of
airway pathogenesis [36, 37], is known to be elevated in
smokers [38] and COPD patients [39], has a negative
correlation with FEV1 in patients with expiratory volumes
below 40 % predicted [40] and increases further during
exacerbations [41].
The importance of CRP, PCT and NE in COPD has
been clearly demonstrated. Yet despite the merits that
saliva could offer to practical monitoring of COPD and
its exacerbations, only two studies have explored its po-
tential clinical role [42, 43]. The aim of our study was
therefore to investigate levels of CRP, PCT and NE in
unstimulated whole saliva using commercially-validated
and modified enzyme-linked immunoassays (ELISA) and
to determine differences between patients with COPD
and controls with normal lung function. Target bio-
markers were measured at 3 time points within a 14-day
period. As smoking can influence steady-state biomarker
levels [44], control groups included life-long never-
smokers and current smokers. COPD data were analysed
relative to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stage (percentage predicted FEV1)
[45], which alongside MRC scores and self-assessment
scores provided information for correlations between
target salivary biomarkers and COPD-relevant clinical
metrics. For further validation, randomly chosen partici-
pants also provided simultaneous blood samples.
Materials & methods
Subject characteristics and study design
From January 2010 to March 2012, individuals were re-
cruited consecutively from our research and outpatientclinic databases to one of 3 cohorts: life-long never-
smokers (NS group); current smokers (S group; with > 20
pack years); or COPD, confirmed by spirometry according
to GOLD criteria [45]. Patients with other respiratory dis-
orders were excluded. All NS and S subjects had normal
lung function. Participants were monitored over 14 days
(3 visits, one week apart). At visit 1, demographic details
were recorded (Table 1) (Additional file 1: Table S1);
participants with any infection or unstable illness in the
preceding 6 weeks were excluded. On each visit, the
Medical Research Council (MRC) dyspnoea score was
recorded [46], spirometry (Koko Legend, nSpire, USA)
performed and unstimulated whole saliva collected
(2 ml). Participants completed a daily self-assessment
diary (Additional file 2) [47], incorporating scores on
breathing, activities of daily living (ADL), sputum features
and cough presence. In-between scheduled visits, patients
were asked to contact the researchers on developing any
change in symptoms. An exacerbation was defined as an
increase in respiratory symptoms for two consecutive days,
with at least two major symptoms (dyspnoea, sputum
purulence, sputum volume) or a major plus a minor symp-
tom (wheeze, cold, sore throat, cough) [48]. Randomly-
selected subjects provided simultaneous saliva and blood
samples. The study was approved by the local research eth-
ics committee [REC project reference: 09/H1203/77]; all
participants gave informed written consent.
Unstimulated whole saliva collection protocol
Participants were asked to abstain from alcohol for at least
12 h; fast for 2 h; refrain from brushing their teeth and
smoking for 30 min, prior to providing saliva samples.
Oral hygiene was checked and mucosal examination per-
formed at each visit. All visit samples were collected at
same time of day for each subject.
Immediately before collection participants rinsed their
mouths with 10mls water; they then sat in an upright pos-
ition, tilted their heads forward, and allowed saliva to pool
in the mouth before passively drooling into an ice-cooled
marked sterile tube (Nunc, Denmark) up-to a total of 2mls.
Collected saliva samples were transported on ice and
stored at − 80 °C until analysis. Prior to analysis, thawed
saliva was centrifuged at 3000 revolutions per minute
(RPM) for 15 min. Sample measurements were undertaken
within 3 months of storage; all biomarker assays were per-
formed in duplicate. All saliva samples were tested for
blood contamination using an 8-parameter urine dip test
strip (Bayer AG, USA). Briefly, 10ul of saliva was aliquoted
onto the reagent square for blood, with the colour change
after 5 s being read on the key and documented.
Analysis of biomarkers in saliva
CRP was measured in 15ul of saliva using a salivary
ELISA kit (Salimetrics Europe, UK) with a detection limit
Table 1 Subject Demographics, Salivary Biomarker & Symptom Profiles
Control Subjects (n = 45) Stable COPD Subjects (n = 62) P value
NS S I II III IV
(n = 20) (n = 25) (n = 62) (n = 12) (n = 19) (n = 25) (n = 6)
Demographics
Age, a years 53 ± 17 42 ± 12 67 ± 7 65 ± 10 64 ± 8 68 ± 5 72 ± 4 <0.001
Gender, male (female) 7 (13) 17 (8) 34 (28) 4 (8) 12 (7) 13 (12) 5 (1) n/a
FEV1,
a % predicted 98.1 ± 3.7 99.7 ± 4.7 55.7 ± 22.0 90.4 ± 9.2 64.4 ± 7.6 44.1 ± 3.7 25.1 ± 4.2 <0.001
BMI, a (kg/m2) 29.8 ± 3.6 25.4 ± 3.3 27.3 ± 7.8 28.0 ± 7.0 28.6 ± 2.6 27.3 ± 1.9 19.8 ± 3.6 <0.379
Co Morbidities
Nil 15 20 27 9 10 5 3 n/a
Gum Disease 2 0 1 0 0 1 0 n/a
Cardiac 3 3 31 2 7 19 3 n/a
Type 2 Diabetes 1 2 10 1 2 7 0 n/a
Treatment
B2 Agonists (Short Acting) 9 19 25 6
B2 Agonists (Long Acting) 8 16 25 6
Anticholinergic (Short Acting) 1 2 3 0
Anticholinergic (Long Acting) 3 8 18 5
Inhaled Steroid 8 17 25 6
Oral Theophyllines 0 1 7 2
Symptom & Sputum Metricsb
MRC Score 1.00, 0.25 1.00, 0.25 4.00, 1.67 3.00, 2.25 4.00, 1.50 5.00, 1.00 5.00, 0.00 <0.001
Breathing Score 2.00, 1.00 2.00, 0.25 3.00, 0.00 3.00, 1.00 3.00, 0.00 3.00, 0.00 3.00, 0.75 <0.001
ADL Score 1.00, 0.00 1.00, 0.00 3.00, 2.00 1.00, 2.00 3.00, 2.00 4.00, 2.33 3.00, 1.50 <0.001
Sputum Amount 1.00, 0.00 1.00, 1.00 2.00, 2.00 1.50, 1.00 2.00, 1.84 3.00, 1.00 2.50, 2.50 <0.001
Sputum Texture 1.00, 1.00 2.00, 0.00 2.00, 0.00 2.00, 0.50 2.00, 0.00 2.00, 0.00 2.00, 0.00 <0.001
Sputum Colour 3.00, 0.00 3.00, 0.00 3.00, 1.00 3.00, 0.75 3.00, 0.83 3.00, 1.00 3.50, 1.00 <0.001
Salivary Biomarkers, b
CRP, ng/ml 0.89, 0.35 1.70, 1.07 1.66, 2.30 1.62, 1.36 2.44, 2.63 1.45, 2.34 2.34, 5.94 <0.002
PCT, ng/ml 0.09, 0.03 0.13, 0.09 0.09, 0.04 0.10, 0.06 0.09, 0.04 0.09, 0.04 0.11, 0.03 <0.012
NE, ng/ml 152, 96 408, 748 189, 508 227, 104 161, 491 189, 687 163, 181 <0.001
I = GOLD stage I, II = GOLD stage II; III = GOLD stage III, IV = GOLD stage IV; ADL = Activity of Daily Living, COPD = Chronic Obstructive Pulmonary Disease;
GOLD = Global Initiative for Chronic Obstructive Lung Disease; NS = healthy non-smoker; S = healthy smoker; FEV1 = Forced Expiratory Volume in 1 s; BMI = Body
Mass Index; ex = ex-smokers; CRP = C-Reactive Protein; PCT = Procalcitonin; NE = Neutrophil Elastase. Data are presented as: a, Mean ± standard deviation; b, Median,
inter-quartile range. Exacerbation frequency is divided into 3 groups: Group 1 = 1–3, Group 2 = 4–6, Group 3 = >6. P values represent the difference between controls
and stable COPD subjects. No significant difference was found across COPD severity defined by GOLD for: Age, BMI, CRP, PCT, NE, Breathing Score, Sputum Texture and
Sputum Colour: (p < 0.379; p < 0.403; p < 0.559; p < 0.946; p < 0.620; p < 0.127; p < 0.228; p < 0.824). FEV1 significantly decreased as COPD severity increased (p < 0.001),
whilst MRC, ADL and Sputum Amount significantly increased: (p < 0.001; p < 0.002; p < 0.011 respectively)
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0.89 ng/ml.
Levels of PCT and NE in saliva were measured fol-
lowing in-house modification of commercially-available
ELISAs [49].
Briefly, for adapting the VIDAS® BRAHMS PCT (bio-
Mérieux, France) for use in saliva, pre-study experiments
involved spiking saliva from non-smoker healthy subjects
with PCT Control (provided by the manufacturer for assaycalibration) in varying concentrations: 0.09–20 ng/ml.
These spiked samples were analysed neat and in varying
defined dilutions: 1:1, 1:2, 1:4, 1:8 using Phosphate Buff-
ered Saline - Tween 20–0.05 % (PBS-T). Optimal recovery
of PCT (85 %) at all concentrations occurred when saliva
was diluted 1:2 in PBS-T. The manufacture’s test proced-
ure for performing the assay was not altered. Thereafter,
PCT was determined in 100ul of saliva diluted 1:2 in
Phosphate Buffered Saline-Tween 20 − 0.05 % (PBS-T)
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detection limit of 0.10 ng/ml; lower concentrations were
assigned as 0.09 ng/ml.
For adapting the PMN-Elastase ELISA Kit (Immun-
diagnostik AG, Germany) for use in saliva, we first
spiked non-smoker healthy saliva with NE (provided by
the manufacturer to calibrate the assay) in varying con-
centrations: 115–1000 ng/ml. These spiked samples were
analysed in varying dilutions: 1:100, 1:200, 1:400, 1:800
using manufacturer-supplied ELISA wash buffer. Recovery
of NE (90 %) was consistent across all 4 dilutions; for
the study we elected to use a 1:200 dilution. The manu-
facture's test procedure for performing the assay was
not altered. Thus, NE was measured in 7.0 ul of saliva
diluted 1:200 in ELISA wash buffer using PMN-Elastase
ELISA Kit (Immundiagnostik AG, Germany), with a de-
tection limit of 70 ng/ml; lower concentrations were
assigned as 69 ng/ml.
Analysis of biomarkers in blood
Peripheral blood was collected in supplement-free tubes
and ethylene diaminetetra-acid vacutainer tubes (BD
Bioscience, New Jersey, USA). Samples were then centri-
fuged at 2000 RPM for 15 min; retrieved serum was
stored at 80 °C until analysis. Serum CRP was measured
using ADVIA 2400 Chemistry System (Siemens AG,
Germany) with detection limit of 0.3 mg/L. Serum PCT
and NE were quantified using same assay kits as for sal-
iva, but following manufacturers’ protocols. Serum levels
were expressed as ng/ml except for CRP (mg/L). All as-
says were performed in duplicate.HealthHealthy - Non Smokers
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Fig. 1 Salivary CRP levels from healthy non-smoker, healthy smokers and stabl
represents the interquartile range. Outliers are identified by o (1.5 x the interquStatistical analysis
Statistical analyses were performed using IBM SPSS
Statistics Version 19 (SPSS Inc, IBM, USA). Parametric
data are expressed as mean ± standard deviation (SD)
and non-parametric as median, (inter-quartile range
[IQR]). Between-group comparison was performed
using Mann–Whitney U test, Kruskal-Wallis one-way ana-
lysis of variance (ANOVA) and for paired data, Wilcoxon
Signed Ranks test. A Bonferroni Correction was applied
when undertaking multiple comparison testing. Biomarker
data were logarithmically transformed to allow Univariate
Analysis and determination of covariate effect. Correlations
were assessed by Spearman’s Rank correlation co-efficient
(r). The reproducibility of salivary biomarker levels was
explored using Bland-Altman plots expressing the
change within a subject. A p value of <0.05 was considered
significant.Results
In total 143 individuals were recruited: 20 never-smokers
(NS) and 25 current smokers, over 20 pack year history,
(S) with normal lung function; 98 COPD patients (GOLD
Stage I, 16; Stage II, 32; Stage III, 39; Stage IV, 11), all ex-
smokers (>20 pack year history). Thirty-six COPD patients
experienced an exacerbation during the course of the
study; all controls remained clinically stable. Salivary CRP,
PCT and NE were measured in all participants (Table 1)
(Additional file 1: Table S1), with an intra-and inter-assay
co-efficient of variances of <7 % and <12 % respectively
for all 3 assays.Stable COPDy - Smokers
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Fig. 2 Bland-Altman plot of baseline salivary CRP levels across healthy non-smokers, health smokers and stable COPD. The upper and lower bars
represent 1.96 Standard Deviations (SD) from the mean. Almost all replicates fell within the 95 % limits of agreement (difference between stable
baseline values), with only 2 outliers
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Only stable COPD patients (n = 62) were included in the
between-group analyses. Salivary CRP differed between
the 3 groups (p < 0.002 by ANOVA), with significant in-
crease in COPD (median: 1.66 ng/ml; IQR: 2.55 ng/ml)
compared to NS (0.89 ng/ml; 0.35 ng/ml, p < 0.001 by
Mann Whitney U), but not to smokers (1.70 ng/ml;
1.07 ng/ml, p < 0.605). Smokers had higher salivary CRPHealthHealthy - Non Smokers
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the box length represents the interquartile range. Outliers are identified by o (than never-smokers (p < 0.001) (Fig. 1). These differences
remained statistically significant (p < 0.05 by Univariate
Analysis) following adjustment for age, gender, sampling
time and total co-morbidities; but not for BMI (p < 0.402).
The coefficient of variance for CRP variability within
subjects was 13 %, 27 %, 15 % for NS, S and stable
COPD respectively. The Bland‐Altman plot with upper
and lower limits (1.96 Standard Deviation (SD))Stable COPDy - Smokers
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Fig. 4 Bland-Altman plot of baseline salivary PCT levels across healthy non-smokers, health smokers and stable COPD. The upper and lower bars
represent 1.96 Standard Deviations (SD) from the mean. Almost all replicates fell within the 95 % limits of agreement (difference between stable
baseline values), with only 4 outliers
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consistency (difference between stable baseline values),
with only 2 outliers (Fig. 2).
Salivary PCT differed between groups (p < 0.012). Sal-
ivary PCT was significantly elevated in smokers
(0.13 ng/ml; 0.09 ng/ml) compared to NS (0.09 ng/ml;
0.03 ng/ml, p < 0.011) and COPD (0.09 ng/ml; 0.04 ng/
ml, p < 0.01); but not between COPD and NS (p <HealtHealthy - Non Smokers
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Fig. 5 Salivary Neutrophil Elastase (NE) from healthy non-smokers, health
median; the box length represents the interquartile range. Outliers are id0.363) (Fig. 3). Following covariate adjustment, there
was no significant difference (p < 0.564) between co-
horts. Gender adjustment showed salivary PCT was
generally lower in females, (0.11 vs. 0.14 ng/ml [males]:
p < 0.05). The coefficient of variance for PCT variability
within subjects was 19 %, 15 %, 14 % for NS, S and
stable COPD respectively. The Bland‐Altman plot with
upper and lower limits (1.96 SD) combing all 3 groupsStable COPDhy - Smokers
p < 0.001
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Fig. 6 Bland-Altman plot of baseline salivary NE levels across healthy non-smokers, health smokers and stable COPD. The upper and lower bars
represent 1.96 Standard Deviations (SD) from the mean. Almost all replicates fell within the 95 % limits of agreement (difference between stable
baseline values), with only 7 outliers
Patel et al. Respiratory Research  (2015) 16:62 Page 7 of 15(n = 107) showed good data consistency, with only 4
outliers (Fig. 4).
Differences in salivary NE were observed between
cohorts (p < 0.001), irrespective of covariate adjust-
ment (p < 0.011). Smokers had significantly raised NE
(408 ng/ml; 748 ng/ml) compared to NS (152 ng/ml;
96 ng/ml, p < 0.001), and COPD patients (189 ng/ml;
508 ng/ml, p < 0.001); with no significant difference be-
tween NS and COPD (p < 0.235) (Fig. 5). Age appeared
to affect salivary NE levels (p < 0.04), with around
60 ng/ml decline for every increasing decade in COPD
patients, regardless of treatment. The coefficient of
variance for NE variability within subjects was 32 %,
41 %, 37 % for NS, S and stable COPD respectively.
The Bland‐Altman plot with upper and lower limits
(1.96 SD) combing all 3 groups (n = 107) showed good
consistency of data (difference between stable baseline
values) with only 7 outliers (Fig. 6).
No association was observed between salivary bio-
markers and COPD severity, as determined by FEV1;
CRP: p < 0.559; PCT: p < 0.946; NE: p < 0.620.Table 2 Correlations of All COPD Subjects (n = 98) Symptom Scores
Symptom Scores
Salivary Biomarkers Breathing Score
CRP r = 0.142, p <0.02
PCT r = 0.125, p <0.04
NE r = 0.105, p <0.082
COPD = Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volum
CRP = C-Reactive Protein; PCT = Procalcitonin; NE = Neutrophil Elastase. Data areSubject-completed symptom scores
All participants completed a daily self-assessment symp-
tom diary (Additional file 2), MRC scores significantly
correlated with breathing scores (r = 0.55; 95 % Confi-
dence Interval (CI): 0.34–0.70) and ADL (r = 0.47; 95 %
CI: 0.25–0.64); p < 0.001 by Spearman’s.
Inter-group analysis demonstrated differences in all
symptom scores between stable COPD, NS and S (p <
0.001). There was no significant difference between NS
and S for any symptom metrics.
Analysis between salivary biomarkers and clinical met-
rics across participants (n = 143) revealed correlation of
salivary CRP with ADL (r = 0.23, p < 0.02); sputum
amount (r = 0.23, p < 0.02) and texture (r = 0.24, p <
0.02). Salivary PCT did not significantly correlate with
any symptom. Salivary NE only correlated with MRC
score (r = 0.29, p < 0.01).
Separate sub-analysis on all COPD patients (n = 98)
(Tables 2 and 3) (Additional file 3: Table S2 & Additional
file 4: Table S3) demonstrated salivary CRP correlated with
MRC score (r = 0.16, p < 0.01), breathing score (r = 0.14,vs. Salivary Biomarker Levels
ADL Score MRC Score
r = 0.105, p <0.08 r = 0.164, p <0.006
r = 0.115, p <0.06 r = 0.04, p <0.444
r = 0.028, p <0.647 r = -0.074, p <0.222
e in 1 s; MRC = Medical Research Council; ADL = Activity of Daily Living;
presented as the Spearman’s correlation coefficient: r value
Table 3 Correlations of All COPD Subject (n = 98) Sputum Metrics vs. Salivary Biomarker Levels
Sputum Metrics
Salivary Biomarkers Sputum Amount Sputum Texture Sputum Colour
CRP r = 0.148, p <0.013 r = 0.130, p <0.032 r = 0.324, p <0.001
PCT r = 0.130, p < 0.033 r = 0.107, p < 0.078 r = 0.229, p < 0.001
NE r = 0.075, p < 0.219 r = -0.118, p < 0.051 r = 0.068, p < 0.266
COPD = Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volume in 1 s; MRC = Medical Research Council; ADL = Activity of Daily Living;
CRP = C-Reactive Protein; PCT = Procalcitonin; NE = Neutrophil Elastase. Data are presented as the Spearman’s correlation coefficient: r value
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texture (r = 0.13, p < 0.03) and colour (r = 0.32, p < 0.001).
Salivary PCT correlated with breathing score (r = 0.13,
p < 0.04) (Fig. 7c), sputum amount (r = 0.13, p < 0.03)
and colour (r = 0.23, p < 0.001). Salivary NE did not
correlate with any clinical features. Sputum amount and
colour correlated with breathing (r = 0.34, p < 0.001) and
ADL scores (r = 0.34, p < 0.001); texture correlated only
with ADL (r = 0.24, p < 0.001) (Table 4) (Additional file 5:
Table S4).Fig. 7 Scatter plot with a best fit line between COPD subject symptom sco
CRP vs. breathing score; c Salivary PCT vs. breathing scoreCOPD Stable vs. Exacerbation
Thirty-six COPD patients experienced an exacerbation at
day 11 ± 3 (Table 5) (Additional file 6: Table S5). There
was no difference in the median baseline exacerbation fre-
quency (1–3 episodes per year) between these patients
and those COPD patients that remained stable throughout
the study. Comparison of their paired stable and pre-
treatment exacerbation samples demonstrated significant
elevation in all target salivary biomarkers at exacerbation
(p < 0.001) (Figs. 8, 9, 10). Levels of CRP increased byres and salivary biomarkers. a Salivary CRP vs. MRC score; b Salivary
Table 4 Correlation of All COPD Subject (n = 98) Symptom Scores vs. Sputum Metrics
Symptom Scores
Sputum Metrics Breathing Score ADL Score MRC Score
Amount r = 0.34, p < 0.001 r = 0.34, p < 0.001 r = 0.24, p < 0.001
Texture r = 0.07, p < 0.24 r = 0.24, p < 0.001 r = 0.31, p < 0.001
Colour r = 0.26, p < 0.001 r = 0.19, p < 0.001 r = 0.28, p < 0.001
COPD= Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volume in 1 s; MRC =Medical Research Council; ADL = Activity of Daily Living; CRP = C-Reactive
Protein; PCT = Procalcitonin; NE = Neutrophil Elastase. Data are presented as the Spearman’s correlation coefficient: r value
Table 5 Same COPD Subjects in Stable and Exacerbation phase
(n = 36) Demographics, Salivary Biomarker & Symptom Profiles
Stable Exacerbation P value
Demographics
Age, a years 68 ± 9
Gender, male (female) 17 (19)
FEV1,
a % predicted 53 ± 23 48 ± 19 < 0.001
BMI, a (kg/m2) 24.0 ± 6.3
Co Morbidities
Nil 5
Gum Disease 2
Cardiac 30
Type 2 Diabetes 4
Treatment
B2 Agonists (Short Acting) 35
B2 Agonists (Long Acting) 32
Anticholinergic (Short Acting) 5
Anticholinergic (Long Acting) 25
Inhaled Steroid 31
Oral Theophyllines 6
Symptom & Sputum Metricsb
Increased Cough, n 0 10 < 0.001
MRC Score 5.00, 1.25 5.00, 1.25 < 0.16
Breathing Score 3.00, 0.00 4.00, 1.00 < 0.006
ADL Score 3.00, 1.00 4.00, 2.00 < 0.014
Sputum Amount 2.00, 2.00 3.00, 2.25 < 0.001
Sputum Texture 1.94, 0.33 2.06, 0.41 < 0.001
Sputum Colour 3.00, 1.00 4.00, 0.41 < 0.05
Salivary Biomarkersb
CRP, ng/ml 1.61, 1.10 7.35, 10.04 < 0.001
PCT, ng/ml 0.09, 0.06 0.50, 0.71 < 0.001
NE, ng/ml 128, 190 769, 1680 < 0.001
COPD= Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volume
in 1 s; BMI = Body Mass Index; ex = ex-smokers; MRC =Medical Research Council;
ADL = Activity of Daily Living; CRP = C-Reactive Protein; PCT = Procalcitonin;
NE = Neutrophil Elastase. Exacerbation frequency is divided into 3 groups:
Group 1 = 1–3, Group 2 = 4–6, Group 3 = >6. Data are presented as: a, Mean ±
standard deviation; b, Median, inter-quartile range. P values represent the
difference between stable and exacerbation phases
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(95 % CI: 0.31–0.54) and NE by 539 ng/ml (95 % CI:
169–982); alongside a reduction in FEV1 (p < 0.001) and
patient-recorded changes in sputum (amount: p < 0.001,
texture: p < 0.05, colour: p < 0.001); ADL and breathing
scores (p < 0.014 and p < 0.006 respectively) (Table 5)
(Additional file 6: Table S5).
Comparison of subject-matched saliva and serum biomarker
levels
Relationships between saliva and serum biomarkers were
studied in 22 randomly-selected subjects, providing a
total of 66 paired saliva-serum samples. Salivary CRP
was approximately 200 times lower than serum; salivary
PCT and NE were about two-fold higher. Salivary CRP
and PCT correlated with serum equivalents, r = 0.82,
(95 % CI: 0.72–0.87), p < 0.001 by Spearman’s; and r =
0.53, (95 % CI: 0.33–0.69), p < 0.006 respectively (Fig. 11a,
11b). Salivary and serum NE did not correlate (r = −0.24,
p < 0.25).
Biomarker cross-analysis demonstrated salivary PCT
correlated with serum and salivary CRP, r = 0.53, (95 % CI:
0.33–0.69), p < 0.006; and r = 0.73, (95 % CI: 0.59–0.83),
p < 0.001 respectively (Fig. 11c, 11d). Salivary NE correlated
with both salivary CRP, r = 0.45, (95 % CI: 0.23–0.63),
p < 0.001, and salivary PCT, r = 0.58, (95 % CI: 0.39–0.72),
p < 0.001 (Fig. 11e, 11f).
Discussion
As disease management shifts increasingly towards point-
of-care, there is urgency to develop easier, less stressful
sampling methods especially for monitoring chronic con-
ditions. This is the first study to explore the potential role
of salivary CRP, PCT and NE in COPD. Whilst a validated
CRP saliva-based assay is available (Salimetrics®), we have
also demonstrated that modification of existing body-fluid
assays (PCT and NE) provides reproducible results for
saliva [50].
Salivary biomarker targets in COPD patients of vary-
ing severity were compared to controls (never-smokers
and smokers) under real world/working conditions;
hence study participants with co-morbid conditions were
included provided these were clinically stable at time of
enrolment. To minimise across-cohort demographic var-
iations and circadian influences, analysed measurements
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Fig. 8 Salivary CRP levels from stable and the same COPD subjects during an exacerbation. The horizontal bar represents the median; the box
length represents the interquartile range. Outliers are identified by o (1.5 x the interquartile range)
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cluding sampling times [52]. Non-smoker salivary CRP
levels at 0.89 ng/ml (IQR 0.35 ng/ml) compared
favourably to previous observations showing a healthy
CRP range of 0.02–2.5 ng/ml in saliva [52–54]. Serum
CRP has been shown to distinguish between COPD and
controls [55], but not healthy smokers from non-smokers
[24]. However no difference in salivary CRP was demon-
strated between our study cohorts following all-covariate
adjustment, possibly because our controls had relativelyStable
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Fig. 9 Salivary PCT levels from stable and the same COPD subjects during
length represents the interquartile range. Outliers are identified by o (1.5 xhigh BMIs; indeed significant differences emerged when
adjustment excluded BMI. In support, strong correlations
between serum CRP and BMI have been previously dem-
onstrated [56]. Whilst correlations between serum CRP
levels and FEV1 have been reported [26, 57], we found no
association between salivary CRP and FEV1 in stable
COPD; this possibly reflects the inhaled corticosteroid
usage in our COPD patients [24].
We are the first to explore the presence of PCT in saliva.
There was no difference in salivary PCT levels betweenExacerbation
an exacerbation. The horizontal bar represents the median; the box
the interquartile range) and * (3 x the interquartile range)
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Fig. 10 Salivary NE levels from stable and the same COPD subjects during an exacerbation. The horizontal bar represents the median; the box
length represents the interquartile range. Outliers are identified by o (1.5 x the interquartile range) and * (3 x the interquartile range)
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covariate adjustment. This is not surprising as PCT is
normally hardly detectable in blood (below 0.05 ng/ml)
unless there is presence of bacterial infections and sepsis
or following trauma [58]. In agreement with previous ob-
servations [38, 59] salivary NE was found to be higher in
smokers, but not in stable COPD patients [60]; possibly
because all study COPD patients were ex-smokers.
The observed increases in salivary CRP, PCT and NE
during COPD exacerbations reflect the well-documented
elevated CRP and PCT in blood [29, 57, 58] and NE in
sputum [41, 59], and have clinical implications. Whilst
salivary CRP (or any of the other analytes) may not be
sufficiently sensitive for evaluating COPD risk and out-
come, it could serve as a potential surrogate for deter-
mining exacerbation onset. However, evidence for CRP
or any biomarker in isolation to confirm an exacerbation
is minimal. On the other hand, our results give support
to future development of single-platform immunodiag-
nostics for near-patient measurement of salivary CRP
alongside other readily available biomarkers e.g., PCT to
enable sufficient confidence for exacerbation prediction
and stratified intervention.
Alongside such developments, we also need to improve
understanding of the association between biomarker/
physiological measurements and patient-reported out-
comes (PRO) in COPD [61]. This is particularly crucial as
no one parameter appears to be sufficiently sensitive or
specific in monitoring disease status or predicting exacer-
bation onset. Our study reveals significant differences in
self-assessed symptom scores and sputum metrics inCOPD patients, similar to studies using SGRQ and CAT
[62]. Furthermore, significant correlations were observed
between salivary levels of CRP and PCT and breathing
scores, with simultaneous changes occurring in both target
analyte levels and patient-reported breathing and ADL
assessments during exacerbations of COPD. As other
PRO instruments have shown similar correlations [47, 63],
it is likely that particular COPD symptoms will be shown
to be driven by underlying inflammatory events, with
those very severe COPD exacerbations requiring hospital-
isation possibly exhibiting different clinical and inflamma-
tory profiles [64].
Thus, biomarkers or symptoms in isolation will not be
sensitive or specific enough to monitor longitudinal
wellbeing in COPD, and combined bio-clinical profiling
is essential, particularly if the long-term goal is to enable
patient-led prediction of exacerbations and prompt
intervention. Indeed, combining serum CRP with one in-
creased major exacerbation symptom (dyspnoea, sputum
volume or purulence) was found to be more sensitive
than CRP alone in diagnosing exacerbations [30]. Of 36
biomarkers analysed, none were sensitive or specific
enough to diagnose exacerbations without symptom as-
sessment [30].
Most serum components are present in saliva, although
compositional differences show that saliva is not a passive
ultra-filtrate of serum [65]. Biomarkers can enter saliva by
cellular diffusion or active transport, ultra-filtration within
salivary glands and/or via the gingival sulcus [66]. The pre-
cise mechanisms explaining CRP, PCT and NE presence in
saliva are unclear. Whilst blood contamination via micro-
A B
C D
E F
Fig. 11 Scatter plot with a best fit line between same subject serum and salivary biomarkers. These subjects provided both serum and saliva
samples on the same visit. a Salivary vs. serum CRP; b Salivary PCT vs. serum PCT; c Salivary PCT vs. serum CRP; d Salivary PCT vs. salivary CRP;
e Salivary NE vs. salivary CRP; f Salivary NE vs. salivary PCT
Patel et al. Respiratory Research  (2015) 16:62 Page 12 of 15
Patel et al. Respiratory Research  (2015) 16:62 Page 13 of 15leakages, crevicular fluid overflow from micro-injuries or
poor oral health is plausible, biomarker measurements in
our study were not affected by adjustment for gum disease;
samples also tested negative for blood.
Both salivary CRP and PCT levels correlated with serum
counterparts. Saliva-serum CRP correlations have been
previously established [54, 67]. Although Ouellet-Morin
et al. observed a moderate to strong association between
saliva and serum CRP, lower correlations were found at
serum CRP below 2.0 mg/L compared to higher CRP
(≥2.0 mg/L) [67]. However, Punyadeera et al. demon-
strated saliva to serum CRP correlation at concentrations
above 5 mg/mL. Whilst these studies suggest that predic-
tion of serum CRP from saliva CRP is more accurate at
higher serum concentrations, our study demonstrated
strong correlations at both low and high CRP levels. The
only study on saliva to serum PCT relationship [68]
showed no significant correlation between the two fluids;
however saliva samples were stored at − 27 °C rather than
the recommended − 80 °C [69].
No correlation was found between saliva and serum
NE levels. Whilst one possible explanation could be
localised NE production not manifesting systemically,
this contradicts the observed moderate to strong correl-
ation of salivary NE to both salivary CRP and PCT
levels. An alternative explanation could be the rapid in-
activation of NE in vivo [70], leading to comparatively
slower inactivation in saliva than serum.
Some study limitations need to be considered. Al-
though subjects had three assessments over 14 days,
longitudinal studies are required to establish steady-
state baselines for the target salivary analytes. These
would offer precise correlations of biomarker changes
to patient-reported outcomes, specifically in the im-
portant prodromal period leading to an exacerbation.
Furthermore, as BMI-matched cohorts appear to influ-
ence salivary CRP between-group differences, BMI sta-
tus may need consideration in future larger studies.
Another possible shortfall is that our study did not
specifically exclude for potential microbial airway col-
onisation in the COPD group, although we did ensure
that participants were excluded in the event of any in-
fection or unstable illness in the preceding 6 weeks to
enrolment. We appreciate that the presence of lower
airway bronchial colonisation can be associated with
elevated serum CRP levels in stable COPD patients
[71], and with increased exacerbation frequency [72].
In mitigation, we have provided separate analysis for
the COPD subjects that underwent an exacerbation
and for those who remained stable throughout the
study; thus minimising bias on target biomarker level
results. Furthermore, there was no difference in median
exacerbation frequency between the exacerbation group
and the stable group, which may indirectly indicatethat airway microbial colonisation was not significantly
different between the 2 groups.
Conclusions
We have established that levels of CRP, PCT and NE can
be reliably and reproducibly measured in saliva, providing
useful clinical information as blood. All 3 target salivary
biomarkers increased during COPD exacerbations, with
CRP and PCT correlating with patient-derived metrics.
These findings provide the conceptual basis for the further
development of salivary biomarkers, alongside PROs,
for practical point-of-care monitoring of COPD and
prediction of exacerbations.
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